App-Quantinova.ai

Association of accelerometer-derived sleep and idiopathic dystonia: A UK Biobank cohort study

G. Bailey - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Dystonia

N/A

Audit of dysphagia care provided to Parkinson’s patients during acute hospital admission

M. Khwaja - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Ballet for Parkinson’s disease, a new concept: Remote delivery via the English National Ballet’s Dance for Parkinson’s programme

A. Podlewska - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Levodopa

Blood neurofilament light chain as a biomarker of Parkinson’s disease

S. Ganesh - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Capturing the complexity of patients with parkinsonism: Baseline characteristics of participants in the PRIME-UK cross-sectional study

E. Tenison - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Cerebrospinal α-synuclein RT-QuIC in pathologically-confirmed Multiple System Atrophy

A. Symonds - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple system atrophy

N/A

Challenges in Outcome Measure Selection in Multi-Arm Multi-Stage Clinical Trials in Parkinson Disease

C. Gonzalez-Robles - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Characterising Natural Killer cells in early Parkinson’s disease

J. Holbrook - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Chronic Visceral Pain in Parkinson’s Disease and Link with White Matter Hyperintensities

K. Rukavina - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

White matter hyperintensities

N/A

Clinically interpretable severity estimation of facial expression impairment in Parkinson’s disease

Y. Dushin - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

COVID-19 encephalitis with anti-mGluR1 antibody-positive cerebellar ataxia

F. Cheng - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Cerebellar Ataxia

N/A

Current Concepts in Physical Therapy and Rehabilitation Protocol for Camptocormia: An Unusual Case Report

S. Calisgan - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Designing a multi-arm multi-stage trial for Parkinson’s

M-L. Zeissler - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Developing infrastructure for a multi-arm multi-stage trial in Parkinson’s

M-L. Zeissler - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Developing New Insights Into Clinical and Genetic Features of PD – The Global Parkinson’s Genetics Program (GP2) Clinical Cohorts Working Group

M. Richer - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Diagnostic Accuracy of Parkinson’s disease: Where Do We Stand?

S. Virameteekul - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Diffusion MRI tractometry findings in Dystonia- A UK Biobank study

C. Maciver - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Dystonia

N/A

Digital Biomarkers for Deep Brain Stimulation Programming in PD

C. Graef - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Dopaminergic medication improves movement vigour in Parkinson’s but not the adaptation of movement speed to curvature

L. Hickman - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Dopamine hydrochloride

Dried blood and plasma spots for the measurement of neurofilament light chain and inflammatory cytokines in patients with REM sleep behaviour disorder

B. Huxford - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Filters

45280 Abstracts